A Surgeon and an Internist Walk Into an Ozempic Debate
Dr. Gary Linkov is a facial plastic surgeon in New York City. His wife, Dr. Liz Grand, is an internal medicine physician. Together, they bring two very different medical perspectives to the Ozempic conversation, and the result is one of the more honest and nuanced discussions you will find on YouTube.
This is not a hype video. It is not an anti-Ozempic hit piece either. It sits in the middle, which is exactly where most people trying to make a decision about GLP-1 drugs need to be.
The Medical Case For and Against
Dr. Grand comes at this from the internist side. She sees patients with obesity, type 2 diabetes, and metabolic syndrome. For her, semaglutide is a real tool with real clinical evidence behind it. She has watched patients lose significant weight and improve their lab numbers in ways that diet and exercise alone had not achieved for them.
Linkov, as a plastic surgeon, sees a different set of consequences. He talks about "Ozempic face," the rapid facial volume loss that happens when people drop weight quickly on GLP-1 drugs. Loose skin, hollowed cheeks, and a gaunt appearance are cosmetic realities that his patients deal with after major weight loss.
Neither of them dismisses the other's perspective. That back-and-forth is what makes the video valuable.
Who Should Actually Be Taking It?
One of the most useful parts of this conversation is the discussion about appropriate candidates. Dr. Grand is clear: semaglutide was developed for people with obesity (BMI 30+) or people with a BMI of 27+ who have weight-related health conditions. It was not designed for someone who wants to lose 10 vanity pounds.
But that is exactly how a lot of people are using it. The cultural adoption of Ozempic has outpaced the clinical guidelines by a wide margin. People with normal BMIs are getting prescriptions through telehealth companies that ask few questions. Both doctors express concern about this trend.
The off-label use raises questions about long-term safety in populations that were never part of the clinical trials. Most semaglutide studies enrolled people with significant obesity or diabetes. We do not have decades of data on what happens when lean people use it for extended periods.
Body Image, Social Media, and Pressure
The conversation takes a personal turn when they discuss the cultural pressure driving Ozempic adoption. Social media has turned weight loss drugs into a lifestyle brand. Celebrities mention them casually. Before-and-after photos flood Instagram and TikTok.
Dr. Grand points out that this creates a strange dynamic in her clinic. Patients come in asking for Ozempic by name, the way they might request a specific brand of shoe. The medicalization of weight loss has merged with consumer marketing in a way that can blur the line between treatment and trend.
Linkov adds the plastic surgery angle: some patients use Ozempic to lose weight and then come to him to fix the cosmetic fallout. It is a cycle that did not exist five years ago.
Side Effects They See in Practice
Both doctors discuss the side effects they encounter in their respective practices. Dr. Grand talks about the GI issues: nausea, constipation, diarrhea, and occasionally more serious concerns like pancreatitis warning signs. She emphasizes that dose titration matters and that patients who ramp up too fast tend to have the worst side effects.
Linkov focuses on the aesthetic side effects. Rapid weight loss from any cause can lead to excess skin, but the speed of GLP-1-induced weight loss can make it worse. Facial aging, sagging skin on the arms and abdomen, and changes in body proportions are all things he sees in consultations.
The Long-Term Question
Both doctors touch on the elephant in the room: what happens when you stop? The data shows that most people regain weight after discontinuing semaglutide. Dr. Grand sees this in her practice regularly. Patients hit their goal weight, feel great, decide they do not need the drug anymore, and within 12 months they are back where they started, sometimes heavier.
This raises a fundamental question about the nature of GLP-1 treatment. Is it a temporary intervention or a lifelong commitment? Linkov notes that this changes the cost calculation significantly. A drug that costs $1,000+ per month forever is a very different proposition than a drug you take for a year.
Dr. Grand frames it clinically: obesity is a chronic disease. You would not stop blood pressure medication because your numbers improved. The same logic may apply to weight management medication. But she acknowledges that this framing does not sit well with everyone, especially people who view medication as a crutch rather than a treatment.
The Weight Regain Data That Should Shape Your Planning
The STEP 1 extension study published in 2022 tracked what happened after participants stopped semaglutide. Within one year of discontinuation, people regained about two-thirds of the weight they had lost. Their cardiometabolic improvements, including blood sugar, blood pressure, and lipid levels, also reversed proportionally.
A separate analysis from the STEP 4 trial compared continuous semaglutide use to switching to placebo after 20 weeks. The placebo group regained weight steadily while the continuation group kept losing. By week 68, the gap between the two groups was dramatic.
This data does not mean GLP-1 drugs are a failure. It means they work more like blood pressure medication than like an antibiotic. You do not take an antibiotic forever because it cures the infection. Blood pressure medication manages an ongoing condition. If you stop, the condition comes back. Obesity, for many people, operates the same way. The biological drivers of weight regain, including hormonal changes, metabolic adaptation, and altered hunger signaling, persist after weight loss regardless of how the weight was lost.
Dr. Grand's point about framing obesity as a chronic disease is backed by this data. If your doctor is planning to eventually take you off semaglutide with no transition strategy, ask what the plan is for the weight regain that the clinical data predicts.
What This Video Gets Right That Most Ozempic Content Misses
The dual-perspective format is the real strength here. Most GLP-1 content comes from a single viewpoint: either a prescriber who sees the metabolic benefits or a critic who sees the downsides. Linkov and Grand sit in the same room and respectfully disagree about priorities. That tension produces a more honest picture than either could create alone.
Grand's insistence on clinical criteria is important. The FDA-approved indications exist for a reason. They reflect the populations where the drugs were studied and where the benefit-to-risk ratio is understood. When healthy-weight people use these drugs, they are in uncharted territory from a safety standpoint.
Linkov's cosmetic perspective adds a dimension that purely medical discussions typically ignore. Doctors who prescribe GLP-1 drugs are focused on metabolic health. They may not think about or mention facial volume loss, loose skin, or the aesthetic consequences of rapid weight change. For patients, these consequences are real and can affect quality of life, self-image, and willingness to continue treatment. The Ozempic face video in our library from Doctor Khalid goes deeper on this specific issue if it concerns you.
A Framework for Deciding Whether GLP-1 Therapy Is Right for You
Based on the questions Grand and Linkov raise, here is a structured way to think through the decision.
Step 1: Check your clinical eligibility honestly. Is your BMI 30 or above? Or 27+ with at least one weight-related condition like type 2 diabetes, hypertension, or sleep apnea? If yes, you fit the studied population. If no, you are in off-label territory with less safety data behind you.
Step 2: Consider your timeline and commitment. Are you willing to take this medication for years, possibly indefinitely? If you view it as a short-term fix, the regain data suggests you may end up back where you started within a year of stopping.
Step 3: Evaluate your support structure. Do you have access to a prescriber who will monitor your progress with regular bloodwork and body composition tracking? Do you have a plan for resistance training and protein intake to minimize muscle loss? The medication works best as part of a system, not in isolation.
Step 4: Factor in the costs, both financial and physical. Monthly medication costs, potential cosmetic side effects, the GI adjustment period, and the lifestyle changes required to maximize results. If any of these are dealbreakers, better to know now than three months in.
The Ethical Dimension
What sets this video apart from most Ozempic content is the ethical thread running through it. Both doctors grapple with the tension between helping patients who genuinely need the medication and enabling a culture that increasingly treats prescription drugs as shortcuts.
They do not land on a simple answer, and that is the point. The decision to start semaglutide should involve a conversation with a doctor who knows your medical history, not a 30-second telehealth screening. If you are on the fence about GLP-1 medications, watching two doctors wrestle with these questions in real time is more helpful than any promotional content or scare piece.
How to Have a Better Conversation With Your Doctor
This video raises questions that most patients do not think to ask. If you are considering GLP-1 medication, here are conversation starters drawn from what Grand and Linkov discuss. Ask your doctor: "Given my BMI and health conditions, do I fit the clinical criteria, or would this be off-label?" Ask: "What is your plan if I reach my goal weight? Is there a protocol for tapering, or should I expect to stay on this long-term?" Ask: "What should I be doing to prevent cosmetic side effects like loose skin and facial volume loss?" And ask: "How will we track whether this is improving my health beyond just weight, things like blood sugar, cholesterol, liver function, and body composition?" These are not confrontational questions. They signal to your prescriber that you are an engaged patient, and they open the door to a more thoughtful treatment plan than a quick prescription and a follow-up in three months.